Clinically, treatment with a GD2-targeting CD27/CD28 CAR-T cells yielded 15% PR and 38% SD in 34 neuroblastoma patients, with a one-year survival rate of 74% (NCT02992210 and NCT02765243) [84]. This evidence concerns the gene CD27 and neuroblastoma.